Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2004

View Archived Issues

Ondansetron found to improve fatigue and depression in chronic hepatitis C

Enrollment opens in phase III trial of MDX-010 for metastatic melanoma

Promising clinical results reported for NicVAX in smoking cessation

Phase II results on the efficacy of Deltavasc in peripheral artery disease

Good safety profile of sargramostim in moderate to severe Crohn's disease

Novel antiinflammatory chalcones patented by Taiwan university researchers

Another series of anti-HIV chemokine CCR5 antagonists presented by Takeda

New anticytomegalovirus agents prepared and tested at Bayer

Cellular Genomics presents new Hsp90 modulators

Novel vanilloid VR1 modulators covered by Amgen patent

New immunomodulators claimed for use in viral infections and cancer

BMS scientists describe new p38 kinase inhibitors

ISTA and Allergan sign new Vitrase agreement

Metvix approved in eight more European countries

Menarini launches frovatriptan in Italy

Favorable review for Neurologix's protocol for epilepsy gene therapy study

BioInvent and ThromboGenics to develop treatments for vascular indications

BTG enters into agreements in field of sleep apnea

Phase I/II study for KAI-9803 in reperfusion injury

AZD-2171 useful in combination with other antitumor agents

Daily administration of A6 well tolerated in gynecological cancer patients

Selenophene derivative induces apoptosis in renal cancer cells

Daily oral CP-724714 well tolerated in first clinical study

Oxis International licenses BXT-51072 and compounds to HaptoGuard

Preliminary clinical results reported for chimeric anti-alpha5beta1 MAb

Therapeutic benefits of Alequel found in patients with moderate to severe CD

Metformin and insulin reported to induce metabolic effects in patients with burns

Studies show biological activity and tolerability of AZD-3409

Two-year follow-up data for TAXUS IV trial

Effects of bovine lactoferrin supplementation in the eradication of H. pylori infection

Alizyme cleared for phase IIb study of ATL-962 for obesity

Approval sought for proof-of-concept study for ATL-1101 in psoriasis

Triple angiokinase inhibitor, BIBF-1120, shows promise for clinical development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...